Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/3/2019
SIETES contiene 92692 citas

 
 
 1 a 20 de 59 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Hershman DL, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, Kengla AT, Melnik MK, Jorgensen CW, Kreisle WH, Minasian LM, Fisch MJ, Henry NL, Crew KD. Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer. A randomized clinical trial. JAMA 2018;319:10 de julio. [Ref.ID 102791]
2. Cita con resumen
Anónimo. Anastrozole: syndromes du canal carpien. Prescrire 2016;36:426. [Ref.ID 100544]
3.Enlace a cita originalTiene citas relacionadas
Mayer EL, Burstein HJ. Postmenopausal breast cancer: a best endocrine strategy?. Lancet 2015;386:1317-9. [Ref.ID 99617]
4. Cita con resumen
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386:1341-52. [Ref.ID 99276]
5.Tiene citas relacionadas
Hugo HS. Hormone theray in premenopausal women with early-stage breast cancer. N Engl J Med 2014;371:175-6. [Ref.ID 97810]
6.Tiene citas relacionadas Cita con resumen
Pagani O, Regan MM, Walley BA, Fleming GF, Collecni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Steams V, Bonnefoi HR, Martino S, Geyer Jr CE, Pinotti G, Puglisi F, Crivellari D, Rushtaller T, Winer EP, Rabaglio-Poretti M, Malbach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA, for the TEXT and SOFT Investigators and the International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014;371:107-18. [Ref.ID 97807]
7. Cita con resumen
Baselga J, Campone M, Piccart M, Burris III HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lewohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9. [Ref.ID 92340]
9. Cita con resumen
Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Waclawski-Wende J, Mctiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farner P, Gelmon KA, Tu D, Richardson H, for the NCIC CTG MAP-3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91. [Ref.ID 90936]
10. Cita con resumen
Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, Mctiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H, for the NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91. [Ref.ID 90725]
11.
Coombes RC, Kilburn LS. Time to TEAM: exemestane, or tamoxifen then exemestane?. Lancet 2011;377:280-1. [Ref.ID 90120]
15. Cita con resumen
Anónimo. Pfizer lifts outlook as Lyrica and Chantix prop up sales in 2007. Scrip 2008;3331:9. [Ref.ID 82104]
16.Tiene citas relacionadas Cita con resumen
Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJH, Delozier T, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM, on behalf of the Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 year's tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559-70. [Ref.ID 79239]
17.Tiene citas relacionadas Cita con resumen
Boccardo F, Rubagotti A. Switching to aromatase inhibitors in early breast cancer. Lancet 2007;369:533-5. [Ref.ID 79230]
18.Enlace a cita original Cita con resumen
Anónimo. NICE advises on tamoxifen alternatives. BMJ 2006;333:1138. [Ref.ID 78638]
19. Cita con resumen
Anónimo. UK recommends aromatase inhibitors but wants more research. Scrip 2006;3213:4. [Ref.ID 78609]
20.
Nabholtz J-M, Gligorov J. Cardiovascular safety profiles of aromatase inhibitors: a comparative review. Drug Saf 2006;29:785-801. [Ref.ID 78085]
Seleccionar todas
 
 1 a 20 de 59 siguiente >>